Crude and adjusted hazard ratios (HR) with 95% confidence intervals (CI) of risk of death or loss-to-follow-up of adolescents after ART initiation (n = 650).

<p>Pediatric IeDEA West Africa Collaboration.</p><p>All analyses used the center as a cluster variable, taking into account the correlation of the observations within a same center.</p><p>HR: Hazard ratio.</p><p>aHR: adjusted hazard ratio.</p><p>MD: missing data.</p><p>ART: Antiretroviral therapy.</p><p>NNRTI: non nucleoside reverse transcriptase inhibitor.</p><p>Severe anemia: haemoglobin≤6.9 g/dL.</p><p>Severe immunosuppression : CD4<200 cells/mm³.</p

Probability of retention in HIV care while on antiretroviral therapy (ART) according to disclosed HIV status taking into account the delayed entry at age of 10 years (n = 650).

<p>Pediatric IeDEA West Africa Collaboration. * Estimation at 36 months from ART initiation.</p

Characteristics of adolescents at HIV disclosure or last contact.

<p>Pediatric IeDEA West Africa (WADA) Collaboration.</p><p>N: number.</p

Characteristics of the process of HIV disclosure of adolescents.

<p>Pediatric IeDEA West Africa (WADA) Collaboration.</p><p>ART: Antiretroviral therapy.</p>*<p>Consisted in other persons of the family (uncle, aunt, grand-mother, grand-father, adoptive father or mother), persons from foster care shelters or NGOs (n = 14), nobody involved because of reading the notice (n = 4).</p

Follow-up characteristics of adolescents on ART.

<p>Pediatric IeDEA West Africa (WADA) Collaboration.</p><p>ART: Antiretroviral therapy.</p><p>N: number; Med: median; IQR: Inter Quartile Range; Min: minimum; Max: maximum.</p

Cohort profile for the adolescent HIV disclosure study.

<p>Pediatric IeDEA West Africa (WADA) Collaboration.</p

Characteristics of adolescents at ART initiation.

<p>Pediatric IeDEA West Africa (WADA) Collaboration.</p><p>ART: Antiretroviral treatment; NNRTI: non nucleoside reverse transcriptase inhibitor;</p><p>N: number; Med: median; IQR: Inter Quartile Range; Min: minimum; Max: maximum.</p